PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092804
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092804
Primary Cells Market size was valued at US$ 1,809.7 Million in 2025, expanding at a CAGR of 9.6% from 2026 to 2033.
The primary cells market is very important for life sciences research and the biopharmaceutical industry. It provides us cells that come directly from animal tissues. These cells retain the characteristics of the tissues they originate from. Primary cells are extremely useful for studying diseases testing medicines and finding new targets for therapy. This is because they resemble real life more than immortalized cell lines. In fact, they account for 68.4 percent of the primary cells used. Animal primary cells are also used a lot making up 31.6 percent. They are often employed to test for toxicity, develop vaccines, and study basic biology. This is due to methods of growing cells in three dimensions, creating organoids, and conducting precision medicine.
According to the World Health Organization (WHO), noncommunicable diseases account for approximately 74% of all deaths globally, while cancer alone was responsible for nearly 20 million new cases and around 9.7 million deaths worldwide in 2022, according to the International Agency for Research on Cancer (IARC). This indicates the primary cells market will continue to be significant as researchers begin using personalized models to develop new medicines. Primary cells will be a part of this.
Primary Cells Market- Market Dynamics
Shift Toward 3D Culture and Personalized Medicine to Drive Market Growth
A big change is happening in the primary cells market. People are moving away from the two-dimensional culture and towards three-dimensional culture formats. These new formats include spheroids, organoids, and organ-on-a-chip systems. This change is happening because two-dimensional culture does not replicate the way cells are arranged, how they communicate with each other, and how they interact with their surroundings in life. This limits how well the results can predict what will happen in life. It also leads to failures in clinical drug development. According to the U.S. Food and Drug Administration (FDA), approximately 90% of drug candidates that enter clinical trials ultimately fail to receive marketing approval, with inadequate efficacy and unexpected safety concerns among the leading causes of failure.
As pharmaceutical and biotechnology companies focus on getting results, they want to use primary-cell-based 3D and organoid platforms more. This increases the demand for quality primary cell stock from donors. This is important for modeling oncology, hepatotoxicity and respiratory disease. According to the National Institutes of Health (NIH), the All of Us Research Program has enrolled more than one million participants, creating one of the world's largest and most diverse biomedical datasets to advance individualized healthcare. This leads to understanding of diseases and development of effective treatments.
The Global Primary Cells Market is segmented on the basis of Type, Origin, Application, End User, and Region.
By type, hematopoietic stem and progenitor cells are in demand because of the growth of CAR-T and other adoptive cell therapy programs. According to the Alliance for Regenerative Medicine (ARM), more than 2,000 regenerative medicine and advanced therapy clinical trials are ongoing globally, many involving hematopoietic stem cells. Keratocyte-based primary cells used to study dermatological diseases, wound healing and ophthalmic diseases. Hepatocytes are very important in drug metabolism and hepatotoxicity testing, as the liver is the site of xenobiotic processing in the human body. According to the World Health Organization (WHO), approximately 254 million people were living with chronic hepatitis B and around 50 million with chronic hepatitis C in 2022, while liver diseases remain a major global health burden. Gastrointestinal primary cells are becoming more popular in research.
Human primary cells are the focus in origin-based segmentation. This is because they closely mimic how humans respond physiologically pharmacologically and genetically. They help us understand health and disease better. Animal primary cells are still crucial for: biological research, veterinary medicine, developing vaccines, and early-stage toxicology studies. The European Commission reported that, around 7.1 million animals were used for research in the EU in 2022. As a result, the demand for primary cells keeps growing. This growth is driven by: precision medicine, gene therapy, and advanced disease models.
Primary Cells Market- Geographical Insights
North America is leading the primary cells market. It has a 47.2% share of demand because the region has biotechnology and pharmaceutical companies. There are also funded research institutions and advanced cell research facilities. According to ClinicalTrials.gov, the United States accounts for more than one-third of all registered clinical studies globally. The U.S. Food and Drug Administration want to use cell-based tests instead of animal testing. This has increased demand for quality human cells. According to the Alliance for Regenerative Medicine (ARM), the United States hosts the largest concentration of regenerative medicine clinical trials worldwide
Asia Pacific is growing fast in the primary cells market. This is due to expanding research facilities and governments are also investing in medicine. It is cheaper to conduct stem cell and primary cell research in Asia Pacific compared to other markets. According to the UNESCO Institute for Statistics, China has become the world's second-largest investor in research and development, while Japan and South Korea consistently rank among the world's highest R&D spenders as a share of GDP. India is the world's vaccine producer. According to the World Health Organization (WHO) and the Department of Biotechnology (Government of India), India supplies approximately 60% of the world's vaccine doses by volume.
The primary cells market has established life sciences suppliers. Thermo Fisher Scientific Inc., Lonza Group AG and Merck KGaA are leaders in primary cells market. They offer cells, culture media, reagents and equipment and they also have distribution networks and invest in manufacturing. According to the Alliance for Regenerative Medicine (ARM) reports that more than 2,000 regenerative medicine and advanced therapy clinical trials are currently underway globally. Specialized suppliers like PromoCell GmbH, STEMCELL Technologies Inc., and ATCC compete on donor characterization and tissue-type offerings. They tailor their products to disease modeling and regenerative medicine research. Other companies, such as BioIVT, Cureline Inc., and iXCells Biotechnologies also compete in the market.
In 2025 Thermo Fisher Scientific bought the Filtration and Separation business from Solventum. This deal made Thermo Fisher Scientific stronger in the area of cell culture media and bioproduction. The cell culture media and bioproduction capabilities of Thermo Fisher Scientific are very important, for its cell and stem cell workflows.
Merck KGaA agreed to acquire HUB Organoids Holding B.V. in 2024, expanding its two-dimensional and three-dimensional cell culture capabilities through organoid modeling technology aimed at accelerating drug development while reducing reliance on animal testing.